Search Results

A Phase II Study Investigating Fruquintinib plus FOLFIRI as Second-Line Treatment for Participants with Metastatic Colorectal Cancer (mCRC) MOA: Fruquintinib is a highly selective and potent VEGFR inhibitor. Key Eligibility Criteria: Subjects must have confirmed mCRC Subjects with genetic aberrations are allowed No MSI-H and BRAF V600 Subjects must have received FOLFOX and BEV-based first…

A phase IIIb study to characterize the efficacy and safety of ADJUVANT ribociclib plus endocrine therapy in a close-to-clinical practice patient population with HR+ HER2- early breast cancer (ADJUVANT WIDER) MOA: Aromatase inhibitor, CDK4/6 inhibitor, LHRH agonist Key Eligibility Criteria: Participant has a histologically and/or cytologically confirmed diagnosis of estrogen-receptor positive and/or progesterone receptor positive…

Michaela is a licensed, board-certified genetic counselor with extensive experience in both clinical and research settings, particularly within the field of cancer genetics. She holds dual bachelor’s degrees in biology and psychology from the University of Maryland, College Park and a master’s degree in Genetic Counseling from Stanford University. Throughout her academic and professional journey,…

Yaquelin Guzman is a board-certified Physician Assistant committed to delivering evidence-based, compassionate care while fostering strong partnerships with patients, families, and the multidisciplinary oncology team. Her professional interests include patient education, symptom management, and optimizing continuity of care throughout the treatment journey. Before becoming a Physician Assistant, Yaquelin spent five years as a Radiation Therapist,…